APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

RNAi Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global RNAi Therapeutics Market Outlook and Growth Opportunities 2026

29 December 2025191 pages

Choose your research edition.

Industry ResearchRNAi Therapeutics Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal RNAi Therapeutics Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal RNAi Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNAi Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal RNAi Therapeutics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global RNAi Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RNAi Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RNAi Therapeutics market include Novartis and Alnylam Pharmaceuticals among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global RNAi Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNAi Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNAi Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global RNAi Therapeutics market.

RNAi Therapeutics Segment by Company

Novartis

Alnylam Pharmaceuticals

RNAi Therapeutics Segment by Type

Subcutaneous Injection

Intravenous Infusion

RNAi Therapeutics Segment by Application

Cancer

Cardiovascular Disease

Genetic Disorder

Other

RNAi Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RNAi Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the RNAi Therapeutics key companies, revenue, market share, and recent developments.

3. To split the RNAi Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions RNAi Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RNAi Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze RNAi Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNAi Therapeutics industry.

Chapter 3: Detailed analysis of RNAi Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of RNAi Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of RNAi Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RNAi Therapeutics Industry Trends Table 2. RNAi Therapeutics Industry Drivers Table 3. RNAi Therapeutics Industry Opportunities and Challenges Table 4. RNAi Therapeutics Industry Restraints Table 5. Global RNAi Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RNAi Therapeutics Revenue Share by Company (2021-2026) Table 7. Global RNAi Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global RNAi Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global RNAi Therapeutics Company, Product Type & Application Table 10. Global RNAi Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Subcutaneous Injection Table 15. Significant Companies of Intravenous Infusion Table 16. Global RNAi Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global RNAi Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global RNAi Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global RNAi Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global RNAi Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Cardiovascular Disease Table 23. Significant Companies of Genetic Disorder Table 24. Significant Companies of Other Table 25. Global RNAi Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global RNAi Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global RNAi Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global RNAi Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global RNAi Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global RNAi Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global RNAi Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global RNAi Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global RNAi Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global RNAi Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global RNAi Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global RNAi Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global RNAi Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global RNAi Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global RNAi Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novartis RNAi Therapeutics Product Portfolio Table 44. Novartis Recent Development Table 45. Alnylam Pharmaceuticals Company Information Table 46. Alnylam Pharmaceuticals Business Overview Table 47. Alnylam Pharmaceuticals RNAi Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Alnylam Pharmaceuticals RNAi Therapeutics Product Portfolio Table 49. Alnylam Pharmaceuticals Recent Development Table 50. Research Programs/Design for This Report Table 51. Authors List of This Report Table 52. Secondary Sources Table 53. Primary Sources List of Figures Figure 1. RNAi Therapeutics Product Image Figure 2. Global RNAi Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNAi Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global RNAi Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Subcutaneous Injection Image Figure 8. Intravenous Infusion Image Figure 9. Global RNAi Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global RNAi Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global RNAi Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Cardiovascular Disease Image Figure 14. Genetic Disorder Image Figure 15. Other Image Figure 16. Global RNAi Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global RNAi Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global RNAi Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global RNAi Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global RNAi Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa RNAi Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa RNAi Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt RNAi Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Cancer
  • Cardiovascular Disease
  • Genetic Disorder
  • Other
Companies covered
  • Novartis
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global RNAi Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global RNAi Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 RNAi Therapeutics Market Dynamics
  1. 2.1 RNAi Therapeutics Industry Trends
  2. 2.2 RNAi Therapeutics Industry Drivers
  3. 2.3 RNAi Therapeutics Industry Opportunities and Challenges
  4. 2.4 RNAi Therapeutics Industry Restraints
3 RNAi Therapeutics Market by Company
  1. 3.1 Global RNAi Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global RNAi Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global RNAi Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global RNAi Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global RNAi Therapeutics Company Product Type and Application
  6. 3.6 Global RNAi Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 RNAi Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 RNAi Therapeutics Market by Type
  1. 4.1 RNAi Therapeutics Type Introduction
  2. 4.1.1 Subcutaneous Injection
  3. 4.1.2 Intravenous Infusion
  4. 4.2 Global RNAi Therapeutics Sales Value by Type
  5. 4.2.1 Global RNAi Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global RNAi Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global RNAi Therapeutics Sales Value Share by Type (2021-2032)
5 RNAi Therapeutics Market by Application
  1. 5.1 RNAi Therapeutics Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Cardiovascular Disease
  4. 5.1.3 Genetic Disorder
  5. 5.1.4 Other
  6. 5.2 Global RNAi Therapeutics Sales Value by Application
  7. 5.2.1 Global RNAi Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global RNAi Therapeutics Sales Value by Application (2021-2032)
  9. 5.2.3 Global RNAi Therapeutics Sales Value Share by Application (2021-2032)
6 RNAi Therapeutics Regional Value Analysis
  1. 6.1 Global RNAi Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNAi Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global RNAi Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global RNAi Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America RNAi Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe RNAi Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific RNAi Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America RNAi Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa RNAi Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa RNAi Therapeutics Sales Value Share by Country, 2025 VS 2032
7 RNAi Therapeutics Country-level Value Analysis
  1. 7.1 Global RNAi Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RNAi Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global RNAi Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global RNAi Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt RNAi Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt RNAi Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt RNAi Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis RNAi Therapeutics Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Alnylam Pharmaceuticals
  8. 8.2.1 Alnylam Pharmaceuticals Company Information
  9. 8.2.2 Alnylam Pharmaceuticals Business Overview
  10. 8.2.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alnylam Pharmaceuticals RNAi Therapeutics Product Portfolio
  12. 8.2.5 Alnylam Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst